IGF-LR3Interpret the evidence
What a 2026 cell-culture study can tell us about one ingredient in a complex medium
2 numbered sourcesSource years 1992, 2026
Peptides are short chains of amino acids joined by peptide bonds, and longer chains can serve as growth signals. IGF-LR3, or Long R3 IGF-1, is an engineered 83-residue analogue of human insulin-like growth factor 1. It has an extension at the beginning and an arginine substitution at position three of the original IGF-1 sequence. A recent study illustrates the difference between using this molecule as a culture ingredient and measuring its individual effects. [1, 2]
In January 2026, researchers described experiments using stromal cells from human umbilical cords. They grew cells under conditions intended to promote characteristics associated with the lining of blood vessels. One culture medium contained Long R3 IGF-1 and other growth signals, including epidermal growth factor and vascular endothelial growth factor. The researchers also used low-oxygen conditions. They then collected small extracellular vesicles, membrane-enclosed particles released by cells, and tested how these particles affected other cells in the laboratory. [1]
The cultured stromal cells changed in several ways, including the production of more vesicles under the combined conditions. The vesicles were associated with effects in laboratory tests of processes involved in vessel formation. Because the experimental condition included a mixture of signals and a change in oxygen, the design did not isolate the role of Long R3 IGF-1. [1]
The paper gives recent primary evidence of the compound's presence in a defined laboratory medium. It does not establish how much the compound contributed to the reported vesicle or cell outcomes, or what it would do in a human treatment setting. This distinction matters whenever a study uses a compound as one of several ingredients. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Francis GL et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology (publication 1992-06). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
